{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:22:04Z","timestamp":1787163724729,"version":"build-2736575974"},"reference-count":36,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,7]]},"DOI":"10.2215\/cjn.08490910","type":"journal-article","created":{"date-parts":[[2011,6,3]],"date-time":"2011-06-03T21:57:13Z","timestamp":1307138233000},"page":"1566-1572","source":"Crossref","is-referenced-by-count":61,"title":["Asymmetric Dimethylarginine and Clinical Outcomes in Chronic Kidney Disease"],"prefix":"10.2215","volume":"6","author":[{"given":"Tse-Min","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Yi","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Ching","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiao-Po","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shing-Jong","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-10-20230601","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1161\/01.CIR.0000095676.90936.80","article-title":"Kidney disease as a risk factor for development of cardiovascular disease: A statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention","volume":"108","author":"Sarnak","year":"2003","journal-title":"Circulation"},{"key":"R2-10-20230601","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1056\/NEJMoa041031","article-title":"Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization","volume":"351","author":"Go","year":"2004","journal-title":"N Engl J Med"},{"key":"R3-10-20230601","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0272-6386(12)80827-4","article-title":"Cardiovascular risk factors in chronic renal failure and hemodialysis populations","volume":"19","author":"Ma","year":"1992","journal-title":"Am J Kidney Dis"},{"key":"R4-10-20230601","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1681\/ASN.2006030204","article-title":"Crosstalk between the kidney and the cardiovascular system","volume":"17","author":"Amann","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"R5-10-20230601","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1161\/CIRCULATIONAHA.110.940932","article-title":"Endothelial dysfunction and subsequent decline in glomerular filtration rate in hypertensive patients","volume":"122","author":"Perticone","year":"2010","journal-title":"Circulation"},{"key":"R6-10-20230601","doi-asserted-by":"crossref","first-page":"5751","DOI":"10.1016\/S0021-9258(18)62716-4","article-title":"Isolation and identification of NG, NG- and NG, N'G dimethyl-arginine, Ne-mono-, di-, and trimethyllysine, glucosylgalactosyl- and galactosyl-delta-hydroxylysine from human urine","volume":"245","author":"Kakimoto","year":"1970","journal-title":"J Biol Chem"},{"key":"R7-10-20230601","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/0140-6736(92)90865-Z","article-title":"Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure","volume":"339","author":"Vallance","year":"1992","journal-title":"Lancet"},{"key":"R8-10-20230601","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/S0008-6363(99)00162-5","article-title":"Biological significance of endogenous methylarginines that inhibit nitric oxide synthases","volume":"43","author":"Leiper","year":"1999","journal-title":"Cardiovasc Res"},{"key":"R9-10-20230601","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1161\/01.CIR.98.18.1842","article-title":"Asymmetric dimethylarginine (ADMA): A novel risk factor for endothelial dysfunction: Its role in hypercholesterolemia","volume":"98","author":"B\u00f6ger","year":"1998","journal-title":"Circulation"},{"key":"R10-10-20230601","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1681\/ASN.V131170","article-title":"Marked increase of asymmetric dimethylarginine in patients with incipient primary chronic renal disease","volume":"13","author":"Kielstein","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"R11-10-20230601","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/sj.ki.5001632","article-title":"ADMA, proteinuria, and insulin resistance in non-diabetic stage I chronic kidney disease","volume":"70","author":"Caglar","year":"2006","journal-title":"Kidney Int"},{"key":"R12-10-20230601","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1681\/ASN.2005020179","article-title":"Asymmetric dimethylarginine and progression of chronic kidney disease: The mild to moderate kidney disease study","volume":"16","author":"Fliser","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"R13-10-20230601","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1681\/ASN.2005010076","article-title":"Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: A competing risks modeling approach","volume":"16","author":"Ravani","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"R14-10-20230601","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1161\/CIRCULATIONAHA.108.838268","article-title":"Plasma asymmetric dimethylarginine and incidence of cardiovascular disease and death in the community","volume":"119","author":"B\u00f6ger","year":"2009","journal-title":"Circulation"},{"key":"R15-10-20230601","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1161\/01.RES.0000181286.44222.61","article-title":"Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease \u2013 results from the AtheroGENE study","volume":"97","author":"Schnabel","year":"2005","journal-title":"Circ Res"},{"key":"R16-10-20230601","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1373\/clinchem.2006.076711","article-title":"Asymmetrical dimethylarginine independently predicts total cardiovascular mortality in individuals with angiographic coronary artery disease (The Ludwigshafen risk and cardiovascular health study)","volume":"53","author":"Meinitzer","year":"2007","journal-title":"Clin Chem"},{"key":"R17-10-20230601","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1016\/S0140-6736(01)07217-8","article-title":"Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: A prospective study","volume":"358","author":"Zoccali","year":"2001","journal-title":"Lancet"},{"key":"R18-10-20230601","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.atherosclerosis.2009.05.011","article-title":"Methyl-arginines and mortality in patients with end-stage renal disease: A prospective cohort study","volume":"207","author":"Aucella","year":"2009","journal-title":"Atherosclerosis"},{"key":"R19-10-20230601","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1016\/j.ehj.2003.08.013","article-title":"Plasma levels of asymmetrical dimethylarginine and adverse cardiovascular events after percutaneous coronary intervention","volume":"24","author":"Lu","year":"2003","journal-title":"Eur Heart J"},{"key":"R20-10-20230601","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.1681\/ASN.2006040368","article-title":"Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease","volume":"17","author":"Ma","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"R21-10-20230601","doi-asserted-by":"crossref","first-page":"747","DOI":"10.2337\/dc07-1762","article-title":"Plasma concentration of asymmetric dimethylarginine (ADMA) predicts cardiovascular morbidity and mortality in type 1 diabetic patients with diabetic nephropathy","volume":"31","author":"Lajer","year":"2008","journal-title":"Diabetes Care"},{"key":"R22-10-20230601","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.2215\/CJN.06671208","article-title":"Asymmetric dimethylarginine and mortality in stages 3 to 4 chronic kidney disease","volume":"4","author":"Young","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"R23-10-20230601","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1161\/01.CIR.101.9.948","article-title":"Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction","volume":"101","author":"Suwaidi","year":"2000","journal-title":"Circulation"},{"key":"R24-10-20230601","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1681\/ASN.2005080834","article-title":"Endothelial dysfunction contributes to renal function-associated cardiovascular mortality in a population with mild renal insufficiency: The Hoorn study","volume":"17","author":"Stam","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"R25-10-20230601","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1053\/j.ajkd.2005.09.029","article-title":"The determinants of endothelial dysfunction in CKD: Oxidative stress and asymmetric dimethylarginine","volume":"47","author":"Yilmaz","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"R26-10-20230601","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1681\/ASN.2005121379","article-title":"Molecular mechanism for elevation of asymmetric dimethylarginine and its role for hypertension in chronic kidney disease","volume":"17","author":"Matsuguma","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"R27-10-20230601","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1093\/ndt\/16.9.1823","article-title":"Hemodialysis improves endothelial function in humans","volume":"16","author":"Cross","year":"2001","journal-title":"Nephrol Dial Transplant"},{"key":"R28-10-20230601","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1681\/ASN.V132490","article-title":"Asymmetric dimethylarginine, C-reactive protein, and carotid intima-media thickness in end-stage renal disease","volume":"13","author":"Zoccali","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"R29-10-20230601","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1046\/j.1523-1755.2002.00437.x","article-title":"Left ventricular hypertrophy, cardiac remodeling and asymmetric dimethylarginine (ADMA) in hemodialysis patients","volume":"62","author":"Zoccali","year":"2002","journal-title":"Kidney Int"},{"key":"R30-10-20230601","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1111\/j.1523-1755.2005.00744.x","article-title":"Nitric oxide preserves the glomerular protein permeability barrier by antagonizing superoxide","volume":"68","author":"Sharma","year":"2005","journal-title":"Kidney Int"},{"key":"R31-10-20230601","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1161\/01.CIR.0000133312.96477.48","article-title":"Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes","volume":"110","author":"Klausen","year":"2004","journal-title":"Circulation"},{"key":"R32-10-20230601","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1016\/j.jacc.2005.04.066","article-title":"Suppression of endothelial progenitor cells in human coronary artery disease by the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine","volume":"46","author":"Thum","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"R33-10-20230601","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1093\/ndt\/gfp439","article-title":"Synergistic effects of asymmetrical dimethyl-L-arginine accumulation and endothelial progenitor cell deficiency on renal function decline during 2-year follow-up in stable angina","volume":"25","author":"Surdacki","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"R34-10-20230601","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1161\/01.ATV.0000136656.26019.6e","article-title":"Asymmetric dimethylarginine produces vascular lesions in endothelial nitric oxide synthase\u2013deficient mice: Involvement of renin-angiotensin system and oxidative stress","volume":"24","author":"Suda","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R35-10-20230601","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.amjcard.2004.03.052","article-title":"Effect of rosuvastatin on plasma levels of asymmetric dimethyl-arginine in patients with hypercholesterolemia","volume":"94","author":"Lu","year":"2004","journal-title":"Am J Cardiol"},{"key":"R36-10-20230601","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/S0895-7061(02)02278-1","article-title":"Angiotensin converting enzyme inhibition and angiotensin II AT 1-receptor blockade reduce the levels of asymmetric dimethylarginine NG,NG -dimethylarginine in human essential hypertension","volume":"15","author":"Delles","year":"2002","journal-title":"Am J Hypertens"}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01277230-201107000-00010","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:40:52Z","timestamp":1786369252000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01277230-201107000-00010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7]]},"references-count":36,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.08490910","relation":{},"ISSN":["1555-9041"],"issn-type":[{"value":"1555-9041","type":"print"}],"subject":[],"published":{"date-parts":[[2011,7]]}}}